Physician profile
David A Brown
NPI 1053314088
$17,059.29
in general payments reported to CMS, 2019-2025
53 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $2,646 · 2021: $3,232 · 2022: $2,366 · 2023: $2,356 · 2024: $2,694 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,986 · Education: $96.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,985.66 |
| Education | $96.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,986.21 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,703.46 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,602.34 | 2020-2025 | |
| Lilly USA, LLC | $1,587.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,173.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,078.87 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $834.11 | 2019-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $724.42 | 2019-2025 | |
| Allergan, INC. | $701.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $673.24 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $672.53 | 2020-2024 | Wellbutrin, Aplenzin |
| Otsuka America Pharmaceutical, INC. | $381.75 | 2019-2025 | Rexulti |
| Exact Sciences Corporation | $376.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $365.97 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $257.92 | 2020-2025 | Livalo, Seglentis, Zoryve |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.